Related references
Note: Only part of the references are listed.An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy
E. Van Cutsem et al.
ANNALS OF ONCOLOGY (2008)
New approaches to assessing and treating early-stage colon and rectal cancers: Cooperative group strategies for assessing optimal approaches in early-stage disease
Al B. Benson
CLINICAL CANCER RESEARCH (2007)
Capecitabine plus oxaliplatin in metastatic colorectal cancer
Jim Cassidy
JOURNAL OF CLINICAL ONCOLOGY (2007)
Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy
Leonard B. Saltz et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Combined antiangiogenesis and antiepidermal growth factor receptor targeting in the treatment of cancer: Hold back, we are not there yet
Jose Baselga et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: The BOND-2 study
Leonard B. Saltz et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer:: Final report of the Spanish cooperative group for the treatment of digestive tumors trial
Eduardo Diaz-Rubio et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Antiangiogenics: The potential role of integrating this novel treatment modality with chemoradiation for solid cancers
Dan G. Duda et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab
Frank A. Scappaticci et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab
Shirin Khambata-Ford et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia
Charles A. Schiffer
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Plasma lysophosphatidylcholine levels: Potential biomarkers for colorectal cancer
Zhenwen Zhao et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): A preliminary analysis of Cancer and Leukemia Group B (CALGB
H. L. Kindler et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Objective response rate in a phase II multicenter trial of pertuzumab (P), a HER2 dimerization inhibiting monoclonal antibody, in combination with trastuzumab (T) in patients (pts) with HER2-positive metastatic breast cancer (MBC) which has progressed during treatment with T
J. Baselga et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200
Bruce J. Giantonio et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Prognosis of stage II colon cancer by non-neoplastic mucosa gene expression profiling
A. Barrier et al.
ONCOGENE (2007)
Epidermal growth factor receptor signaling is required for microadenoma formation in the mouse azoxymethane model of colonic carcinogenesis
Alessandro Fichera et al.
CANCER RESEARCH (2007)
Sunitinib: From rational design to clinical efficacy
Laura Q. M. Chow et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Cancer statistics, 2007
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2007)
Target practice: Lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer
Maartje Los et al.
ONCOLOGIST (2007)
Opinion - Angiogenesis: an organizing principle for drug discovery?
Judah Folkman
NATURE REVIEWS DRUG DISCOVERY (2007)
Epidermal growth factor receptor activation: How exon 19 and 21 mutations changed our understanding of the pathway
Rafael Rosell et al.
CLINICAL CANCER RESEARCH (2006)
Targeting the expression of platelet-derived growth factor receptor by reactive stroma inhibits growth and metastasis of human colon carcinoma
Yasuhiko Kitadai et al.
AMERICAN JOURNAL OF PATHOLOGY (2006)
NPI-0052 enhances tumoricidal response to conventional cancer therapy in a colon cancer model
James C. Cusack et al.
CLINICAL CANCER RESEARCH (2006)
Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines
Heinz-Josef Lenz et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Reversible posterior leukoencephalopathy syndrome after bevacizumab/FOLFIRI regimen for metastatic colon cancer
Jeffrey A. Allen et al.
ARCHIVES OF NEUROLOGY (2006)
Lymph node status and TS gene expression are prognostic markers in stage II/III rectal cancer after neoadjuvant fluorouracil-based chemoradiotherapy
Torsten Liersch et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases
JN Vauthey et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Prognostic significance of epidermal growth factor receptor expression in colon cancer patients undergoing curative surgery
Gennaro Galizia et al.
ANNALS OF SURGICAL ONCOLOGY (2006)
Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line
A Grothey et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
The epidermal growth factor receptor tyrosine kinase inhibitor gefitinib sensitizes colon cancer cells to irinotecan
AH Braun et al.
ANTI-CANCER DRUGS (2005)
Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer
T Kuo et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Early antiangiogenic activity of SU11248 evaluated in vivo by dynamic contrast-enhanced magnetic resonance imaging in an experimental model of colon carcinoma
P Marzola et al.
CLINICAL CANCER RESEARCH (2005)
Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: A Multicenter study of the Gruppo Oncologico Dell'Italia Meridionale
G Colucci et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma - Final results of the southern Italy cooperative oncology group trial 0108
P Comella et al.
CANCER (2005)
Proteasome inhibitors-mediated TRAIL resensitization and Bik accumulation
HB Zhu et al.
CANCER BIOLOGY & THERAPY (2005)
Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry
KY Chung et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Drug therapy - Systemic therapy for colorectal cancer
JA Meyerhardt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy
Mario Boccadoro et al.
CANCER CELL INTERNATIONAL (2005)
Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan
F Innocenti et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor
LB Saltz et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment
A Grothey et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Gene expression profiling of human colon xenograft tumors following treatment with SU11248, a multitargeted tyrosine kinase inhibitor
AM Morimoto et al.
ONCOGENE (2004)
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer:: A randomized GERCOR study
C Tournigand et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: An updated meta-analysis
P Piedbois
JOURNAL OF CLINICAL ONCOLOGY (2004)
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer
D Cunningham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Mortality associated with daily bolus 5-fluorouracil/leucovorin administered in combination with either irinotecan or oxaliplatin - Results from Intergroup Trial N09741
T Delaunoit et al.
CANCER (2004)
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
H Hurwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
A Randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer
RM Goldberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Colon cancer survival rates with the new American Joint Committee on cancer sixth edition staging
JB O'Connell et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2004)
Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer
CM Ribic et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: Interim results of a phase III trial
ML Rothenberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU) leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer
F Kabbinavar et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer
JY Douillard et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer
J Carmichael et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
First-line oral capecitabine therapy in metastatic colorectal cancer:: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin
J Cassidy et al.
ANNALS OF ONCOLOGY (2002)
A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients
DJ Sargent et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Molecular predictors of survival after adjuvant chemotherapy for colon cancer.
T Watanabe et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer.
LB Saltz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis
M Buyse et al.
LANCET (2000)
Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients
J Schüller et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2000)
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial
JY Douillard et al.
LANCET (2000)
Share Paper
